Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02168803 | A Study of Evacetrapib in Participants With Abnormal Cholesterol | PHASE1 | COMPLETED | 101 | — | — | May 1, 2014 | Dec 1, 2015 | Oct 3, 2018 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Evacetrapib: Single Dose | EXPERIMENTAL | Single oral dose of evacetrapib on Day 1 |
| Evacetrapib: Multiple Dose 12 Weeks | EXPERIMENTAL | Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks |
| Evacetrapib: Multiple Dose 24 Weeks | EXPERIMENTAL | Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks |
| Evacetrapib: Multiple Dose 52 Weeks | EXPERIMENTAL | Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks |
| Name | Type | Description |
|---|---|---|
| Evacetrapib | DRUG | Administered orally |
Inclusion Criteria: * Generally healthy participants or have stable medical conditions that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the participant at increased risk by participating in the study, and will not interfere with interpret...